GNPX
What one share of Genprex holds
Pharmaceutical Preparations
We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.
Genprex’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$14.72 |
|---|---|
| Cash and investments | $29.94 |
| Book value | $29.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.00 | −$1,010 | $0.99 | −$785.56 | — | $1,434 |
| 2021 | $0.00 | −$840.00 | $1.35 | −$607.96 | — | $1,724 |
| 2022 | $0.00 | −$990.15 | $0.00 | −$734.94 | — | $926.05 |
| 2023 | $0.00 | −$1,128 | — | −$904.36 | — | $249.56 |
| 2025 | — | −$17.40 | — | −$16.42 | — | $53.15 |